Sodium ricinoleate

321.45100

321.24100

226-191-2

OOO64813BX

DTXSID9026005

White or slightly yellow powder

2918199090

57.53000

5.07930

Ricinoleic acid, sodium salt is a white powder. (NTP, 1992)

0.957 g/cm3

416.4ºC

219.8ºC

219.8ºC

Soluble (NTP, 1992)

Odorless or almost odorless

Aqueous solution is alkaline

Combustible

Water soluble.

Alcohols and Polyols

An alcohol substituted, unsaturated aliphatic basic organic salt. Aqueous solutions are alkaline. Materials in this group are generally soluble in water. The resulting solutions contain moderate concentrations of hydroxide ions and have pH's greater than 7.0. They react as bases to neutralize acids. These neutralizations generate heat, but less or far less than is generated by neutralization of the bases in reactivity group 10 (Bases) and the neutralization of amines. They usually do not react as either oxidizing agents or reducing agents but such behavior is not impossible.

VJ3500000

SRP: Criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

SMALL SPILLS AND LEAKAGE: Dampen spilled material with water to avoid dust, then transfer material to a suitable container. Use absorbent paper dampened with water to pick up remaining material. Wash surfaces well with soap and water. Seal all wastes in vapor tight plastic bags for eventual disposal. STORAGE PRECAUTIONS: Store in a refrigerator or in a cool, dry place. (NTP, 1992)

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

ACUTE/CHRONIC HAZARDS: Low toxicity. (NTP, 1992)

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop. SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment. INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. If symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop, call a physician and be prepared to transport the victim to a hospital. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA) should be used; if not available, use a level of protection greater than or equal to that advised under Protective Clothing. INGESTION: DO NOT INDUCE VOMITING. If the victim is conscious and not convulsing, give 1 or 2 glasses of water to dilute the chemical and IMMEDIATELY call a hospital or poison control center. Be prepared to transport the victim to a hospital if advised by a physician. If the victim is convulsing or unconscious, do not give anything by mouth, ensure that the victim's airway is open and lay the victim on his/her side with the head lower than the body. DO NOT INDUCE VOMITING. IMMEDIATELY transport the victim to a hospital. (NTP, 1992)

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/|/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/|/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

/SIGNS AND SYMPTOMS/ Sodium ricinoleate, as a surfactant, demonstrates predictable skin and mucus membrane irritant effects, and may induce a Type IV dermal sensitization response in those previously sensitized to it. However, food-grade castor oil and sodium ricinoleate are prepared in such a manner as to be free of the castor bean constituents that have been proven to be the source of reported Type I immediate hypersensitivity responses.|/SIGNS AND SYMPTOMS/ Castor oil is known for its purgative effects and can be used to induce labor. Both castor oil and ricinoleic acid are approved for use in food. The mechanistic basis for purgative actions likely includes the membrane-disruptive effects of detergent-like molecules, such as sodium ricinoleate (a "soap"). These effects have been shown to be dose-related and to exhibit a threshold below which no laxative response was evident, in both animals and in humans.|/ALTERNATIVE and IN VITRO TESTS/ ... The cytotoxicity of sodium ricinoleate and other fatty acid sodium salts in human saphenous vein endothelial cell cultures was evaluated. Cell count, trypan blue exclusion, and (3H)leucine incorporation into total cell-associated and released proteins were monitored. For the latter of the three, trichloroacetic acid precipitation of total cell extracts and cell supernates was performed. At concentrations less than or equal to 25 uM, sodium ricinoleate and other fatty acid sodium salts did not induce significant toxicity (based on cell count and trypan blue exclusion) for periods up to 72 hr prior to cytokine stimulation.|/ALTERNATIVE and IN VITRO TESTS/ ... The relationship between structural differences in fatty acids and the inhibition of endothelial activation, taking into consideration that dietary long-chain fatty acids may influence processes that involve endothelial activation (eg, inflammation and atherosclerosis) /were evaluated/. To test for a potential stimulatory effect of fatty acids on adhesion molecule expression, sodium salts of saturated, monounsaturated (sodium ricinoleate included), and n-6 and n-3 polyunsaturated fatty acids were each incubated alone (test concentration = 25 uM) with human saphenous vein endothelial cells (HSVECs) for 72 hr. The 72-hr incubation period was followed by 16 hr of stimulation with the cytokine interleukin (IL)-1alpha in the continuous presence of fatty acid salt. At the end of the incubation period, vascular cell adhesion molecule-1 (VCAM-1) expression was assessed using a cell surface enzyme immunoassay (EIA). Sodium ricinoleate significantly inhibited (considered modest; p < .05) cytokine-induced endothelial adhesion molecule expression. DHA inhibited VCAM-1 expression (p < .01) most potently. /Investigators/ also conducted an experiment to determine whether the fatty acid sodium salts may induce endothelial activation in the absence of cytokines. The salts were incubated with endothelial cell monolayers for 24 hr. Incubation periods prior to detection of adhesion molecule surface expression varied from 0 to 72 hr. Neither sodium ricinoleate (25 uM) nor any other fatty acid sodium salt induced adhesion molecule expression, as assessed by EIA.

9-Octadecenoic acid, 12-hydroxy-, sodium salt (1:1), (9Z,12R)-: ACTIVE|Potassium Ricinoleate, Sodium Ricinoleate, and Zinc Ricinoleate are included in the list of substances employed in the production of resinous and polymeric coatings that have been declared safe for use as the food-contact surface of articles intended for use in producing, manufacturing, packing, processing, preparing, treating, packaging, transporting, or holding food.

Cosmetics -> Cleansing; Emulsifying